RNA · Atrium Therapeutics

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California. Atrium Therapeutics, Inc. was formerly a subsidiary of Avidity Biosciences, Inc.

10578 Science Center Drive, Suite 125, San Diego, CA, 92121, United States
Biotechnology
Healthcare

Market Cap

149.3M

52 Wk Range

$6.36 - $16.77

Previous Close

$6.98

Open

$7.01

Volume

319,659

Day Range

$6.88 - $7.44

Enterprise Value

-82.12M

Cash

232.1M

Avg Qtr Burn

-25.37M

Insider Ownership

3.30%

Institutional Own.

66.71%

Qtr Updated

Sep 30th 2026